Nigerian lady, Halima Shuwa, bags Student of the Year Award at Manchester University
A Nigerian lady, Halima Ali Shuwa, has been recognised by the reputable University of Manchester and awarded with Student of the Year Award.
Ruth Macarthy, a doctoral researcher at Salford University, announced this on LinkedIn on Wednesday.
“Sitting in Whitworth Hall today, at the prestigious University of Manchester, was one of my proudest moments as a Nigerian. It was the moment Halima Ali Shuwa was called up [to] the podium to receive the “Student of the Year” award from the President of the university.” Ms Macarthy wrote.
While presenting the award, the President of the university stated that Halima was chosen because of her dedication and selfless commitment to research excellence.
The President added that Halima dedicated a huge amount of time to researching the immune response in the blood of hospitalised COVID-19 patients – and predicting which patients will further develop long-term covid complications.
She was the first to publish on the associated long-term changes with fatigue and breathlessness in patients who would subsequently develop long covid.
Halima, a recipient of the prestigious Petroleum Technology Development Fund (PTDF) scholarship, hails from Shuwa town of Madagali Local Government Area of Adamawa State. She was born, brought up and schooled in Maiduguri, Borno State.
Halima studied Bachelor of Medical Laboratory Science at the University of Maiduguri, MSc Immunology at Usmanu Danfodiyo University, Sokoto, and then got a PTDF scholarship to the University of Manchester, where she did her PhD in Immunology.
She has published seven papers in high-impact journals during her studies and has four more papers under review.
Towards the end of her PhD, Halima managed to secure multiple job offers from the University of Manchester and several pharmaceutical companies. Finally, she accepted the job offer from GSK (GlaxoSmithKline), where she’ll continue her cutting-edge research to discover an alternative cancer treatment targeting B cells in Immuno-Oncology settings.
